Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.

Stocks | Futures | Watchlist | More
or

Aytu Biopharma Inc (AYTU)

Aytu Biopharma Inc (AYTU)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 129,294
  • Shares Outstanding, K 17,883
  • Annual Sales, $ 27,630 K
  • Annual Income, $ -13,620 K
  • 60-Month Beta -0.27
  • Price/Sales 4.64
  • Price/Cash Flow N/A
  • Price/Book 1.14
Trade AYTU with:

Options Overview

Details
  • Implied Volatility 109.35%
  • Historical Volatility 63.82%
  • IV Percentile 92%
  • IV Rank 100.00%
  • IV High 109.35% on 04/12/21
  • IV Low 78.27% on 04/09/21
  • Put/Call Vol Ratio 0.07
  • Today's Volume 139
  • Volume Avg (30-Day) 131
  • Put/Call OI Ratio 0.01
  • Today's Open Interest 3,910
  • Open Int (30-Day) 6,468

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 3 analysts offering recommendations.
Earnings Estimates - Current Qtr 03/31/21
See More
  • Average Estimate -0.32
  • Number of Estimates 1
  • High Estimate -0.32
  • Low Estimate -0.32
  • Prior Year -1.50
  • Growth Rate Est. (year over year) +78.67%

Price Performance

See More
Period Period Low Period High Performance
1-Month
6.80 +0.59%
on 04/12/21
11.76 -41.86%
on 03/18/21
-1.75 (-20.37%)
since 03/12/21
3-Month
6.66 +2.70%
on 03/05/21
11.76 -41.86%
on 03/18/21
-0.42 (-5.85%)
since 01/12/21
52-Week
5.86 +16.72%
on 12/15/20
21.30 -67.89%
on 04/27/20
-7.46 (-52.17%)
since 04/09/20

Most Recent Stories

More News
Aytu BioPharma Adds Late-Stage Pediatric Onset Rare Disease Asset to Development Pipeline from Rumpus Therapeutics

Aytu gains global license to pivotal study-ready protein kinase C β isoform (PKCβ) inhibitor, AR101 (enzastaurin) in rare disease indications Program initially targeting vascular Ehlers-Danlos Syndrome...

AYTU : 6.84 (-5.39%)
Zacks.com featured highlights include: Avid Bioservices, Oncternal Therapeutics, Amtech Systems and Aytu Biopharma

Zacks.com featured highlights include: Avid Bioservices, Oncternal Therapeutics, Amtech Systems and Aytu Biopharma

ASYS : 11.61 (-6.14%)
AYTU : 6.84 (-5.39%)
CDMO : 18.93 (-2.37%)
ONCT : 6.76 (-18.16%)
5 Stocks to Buy on New Analyst Coverage

Increased analyst coverage over the last few weeks might lead to solid price appreciation for stocks like Interactive Brokers (IBKR), Avid (CDMO), Oncternal (ONCT), Amtech (ASYS) and Aytu.

IBKR : 74.07 (-0.54%)
ASYS : 11.61 (-6.14%)
AYTU : 6.84 (-5.39%)
CDMO : 18.93 (-2.37%)
ONCT : 6.76 (-18.16%)
Aytu BioPharma Strengthens Leadership Team with Appointment of Richard Eisenstadt as Chief Financial Officer

ENGLEWOOD, CO / ACCESSWIRE / April 5, 2021 / Aytu BioPharma, Inc. (NASDAQ:AYTU), a specialty pharmaceutical company focused on commercializing novel therapeutics and consumer healthcare products, today...

AYTU : 6.84 (-5.39%)
Aytu BioPharma Divests U.S. Rights to Natesto(R) to Acerus Pharma

Strategic Transaction Provides $7.5M in Non-Dilutive Capital and Enables Pediatric and ADHD Product Focus Following the Recently Closed Merger with Neos Therapeutics

NEOS : 1.1500 (-2.54%)
AYTU : 6.84 (-5.39%)
Aytu BioScience Announces Close of Merger with Neos Therapeutics

$100M revenue specialty pharmaceutical company on an accelerated path to profitability[1] Company name change to Aytu BioPharma, Inc. becomes effective today Former Neos Therapeutics board members Beth...

NEOS : 1.1500 (-2.54%)
AYTU : 6.84 (-5.39%)
Aytu Bioscience, Inc. (AYTU) Moves 9.2% Higher: Will This Strength Last?

Aytu Bioscience, Inc. (AYTU) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might help the stock continue moving higher in the near...

AYTU : 6.84 (-5.39%)
Thinking about buying stock in Inovalon Holdings, OpGen, Shift Technologies, Surface Oncology, or Aytu Bioscience?

, /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for INOV, OPGN, SFT, SURF, and AYTU.

INOV : 30.03 (+0.27%)
SFT : 8.53 (-2.29%)
SURF : 7.23 (-9.06%)
AYTU : 6.84 (-5.39%)
OPGN : 2.56 (-4.12%)
Aytu BioScience Announces Positive Clinical Results from Healight(TM) Pilot Study in SARS-CoV-2 Patients

Data indicate endotracheal UVA light catheter therapy reduces SARS-CoV-2 viral load and improves clinical outcomes in mechanically ventilated SARS-CoV-2 patients

AYTU : 6.84 (-5.39%)
Aytu BioScience to Present at Upcoming March Investor Conferences

ENGLEWOOD, CO / ACCESSWIRE / February 24, 2021 / Aytu BioScience, Inc. (NASDAQ:AYTU), a specialty pharmaceutical company focused on commercializing novel products that address significant patient needs,...

AYTU : 6.84 (-5.39%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 64% Sell with a Average short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

The market is in highly oversold territory. Beware of a trend reversal.

See More Share

Business Summary

Aytu BioScience, Inc. is a healthcare company which focused on commercialization of novel products in the field of urology. The company's marketed products consists of ProstaScint(R), Primsol(R) and MiOXSYS(TM) which addresses prostate cancer, urinary tract infections, male infertility and male sexual...

See More

Key Turning Points

3rd Resistance Point 7.59
2nd Resistance Point 7.43
1st Resistance Point 7.13
Last Price 6.84
1st Support Level 6.67
2nd Support Level 6.51
3rd Support Level 6.21

See More

52-Week High 21.30
Fibonacci 61.8% 15.40
Fibonacci 50% 13.58
Fibonacci 38.2% 11.76
Last Price 6.84
52-Week Low 5.86

See More

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar